Nature.com: HPBCD treatment improves learning and executive function in Alzheimer model mice

Earlier we have reported on a patent appication related to HPBCD treatment in Alzheimer’s disease based on the invention of Dr. Tsai’s group at MIT:

MIT scientists filed patent for HPBCD treatment in Alzheimer’s disease

Now, the research has been reported also by journal Nature on 16 November 2022, (Blanchard, J.W., Akay, L.A., Davila-Velderrain, J. et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature (2022). https://doi.org/10.1038/s41586-022-05439-w), which is at the time being open access, through this link:

https://www.genengnews.com/neurological-disorders/alzheimers/alzheimers-apoe4-impairs-myelination-through-cholesterol-dysregulation/

The main conclusion of the research:

The team treated some APOE4-expressing mice (APOE4 is the strongest risk factor gene for Alzheimer’s disease) with cyclodextrin, left others untreated, and subjected them all to two different memory tests.  The cyclodextrin-treated mice performed both tests significantly better, suggesting an association between improved myelination and improved cognition.

Based on these research data a clear picture is emerging in which intervening to correct specific lipid dysregulations by cell type could potentially help counteract APOE4’s contributions to Alzheimer’s pathology.